Vasoconstrictor Agents

09/01/2011 - "Finally albumin represents, associated with vasoconstrictors, the therapeutic gold standard for the hepatorenal-syndrome (HRS). "
11/01/2013 - "In combination with vasoconstrictors, albumin is useful in the management of patients with hepatorenal syndrome. "
09/01/2013 - "Various vasoconstrictors have shown promising results in the management of type 1 hepatorenal syndrome (HRS). "
06/01/2012 - "Various vasoconstrictors are useful in the management of hepatorenal syndrome (HRS). "
01/01/2015 - "The efficacy of vasoconstrictors in hepatorenal syndrome (HRS) is variable. "

10/01/1991 - "These results show the rapid development of functional and structural changes in small resistance arteries in renal hypertensive rats within 4-6 wk of hypertension, with significant reduction in external and lumen diameters, increased media width, and increased media-to-lumen ratio, which enhance vascular reactivity to vasoconstrictors, in particular NE and AVP."
05/01/2007 - "Studies in rat aorta have shown that the Na-K-2Cl cotransporter NKCC1 is activated by vasoconstrictors and inhibited by nitrovasodilators, contributes to smooth muscle tone in vitro, and is upregulated in hypertension. "
12/01/2010 - "Rgs2-deficient mice show increased sensitivity and prolonged responsiveness to vasoconstrictors, and genetic variations in the RGS2 gene are associated with hypertension in humans. "
03/01/2008 - "Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors?"
03/01/2007 - "There was no evidence of vascular amplification of the effects of vasoconstrictor agents, indicating that this did not play a role in the development of hypertension."

04/01/2014 - "Treatment of acute variceal bleeding is systematized in the literature, combination of vasoconstrictor drugs and endoscopic therapy, provided significant decline in mortality over the last decades. "
02/01/2011 - "To reduce vascularisation before surgery through the application of topical vasoconstrictors, decreases the rate of intraoperative bleeding, improves the dynamics of the surgery and reduces the difficulty in surgical performance. "
02/01/2010 - "Vasoconstrictors were shown to control approximately 80% of the bleeding episodes and are generally used as a first-line therapy. "
05/01/2009 - "A second indication for HSC accounts for those patients who suffer blood disorders or have sensitivities to certain medications, such as vasoconstrictors, and in whom it is crucial to manage bleeding during surgery. "
10/01/2008 - "A second indication for HSC is for those patients who suffer blood disorders or sensitivity to certain medications, such as vasoconstrictors, and in whom it is crucial to manage bleeding during surgery. "

03/01/2010 - "Despite high doses of vasoconstrictors, treatment has low mortality, minimal end-organ ischemic damage or systemic acidosis, and results in improved caliber of cerebral vessels affected by vasospasm."
05/01/2014 - "However, how to correct severe acidosis to improve the efficacy of vasoconstrictors in hemodynamically unstable patients is still debated. "
05/01/2014 - "The results of the present study also suggest that acidosis might potentiate arterial responsiveness to vasoconstrictors, mostly by way of the α1D-adrenoceptor."
05/01/2014 - "The present study investigated whether severe extracellular acidosis influences the vasoactive properties of vasoconstrictors on human isolated arteries. "
06/01/1958 - "Vasopressor agents; influence of acidosis on cardiac and vascular responsiveness."

01/01/2009 - "The observed effects cannot account for pulmonary hypertension in diabetes, rather the impaired reactivity to vasoconstrictors would counteract the development of pulmonary hypertensive disease."
04/01/2005 - "The neonate is at high risk of developing pulmonary hypertension, which may reflect a misbalance between vasodilator and vasoconstrictor agents. "
01/01/2002 - "These vasoconstrictors showed different systemic and pulmonary haemodynamic effects in patients with chronic pulmonary hypertension as compared to acute pulmonary hypertension. "
11/01/2001 - "The use of vasodilator gene overexpression and antisense knockdown of vasoconstrictors to reduce blood pressure in animal models of systemic and pulmonary hypertension offers the prospect of gene therapy for human hypertensive disease. "
03/01/1988 - "It would be a mistake to summarily dismiss the possible involvement of vasoconstrictors in chronic pulmonary hypertension, but the apparent difficulty in establishing their importance emphasizes that mediators of vascular cell migration, proliferation, synthesis, and secretion may be at least as important in the etiology of the increased vascular resistance as the mediators of vascular tone."